Table 1 Clinical characteristics of study participants.

From: Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring

  All (n = 123) SU group (n = 63) Non-SU group (n = 60) p-value
Age, years 59.9 ± 14.3 61.2 ± 12.8 58.5 ± 15.7 0.472
Gender, male/female 70/53 31/32 39/21 0.077
BMI, kg/m2 26.9 ± 5.8 26.9 ± 5.5 27.0 ± 6.2 0.832
Diabetes duration, year 8.4 ± 1.6 10.7 ± 8.4 7.8 ± 9.2 0.006*
Diabetes complications
 Neuropathy, n (%) 64 (52.0) 35 (55.6) 29 (48.3) 0.423
 Retinopathy, n (%) 26 (21.1) 15 (23.8) 11 (18.3) 0.457
 Nephropathy, n (%) 32 (26.0) 18 (28.6) 14 (23.3) 0.508
 Micro-angiopathy, n (%) 75 (61.0) 40 (63.5) 35 (58.3) 0.558
 Macro-angiopathy, n (%) 20 (16.3) 8 (12.7) 12 (20.0) 0.273
 Fast blood glucose, mg/dl 132.0 ± 30.4 133.6 ± 27.1 130.4 ± 33.7 0.284
 HbA1c, % 8.4 ± 1.6 8.5 ± 1.6 8.4 ± 1.5 0.658
 eGFR, ml/min/1.73m2 75.5 ± 23.9 75.0 ± 22.7 76.0 ± 25.4 0.588
Number of medications, n (%)
 1 drug 48 (39.0) 36 (60.0) 12 (19.0)  < 0.001*
 2 drugs 44 (35.8) 20 (33.3) 24 (38.1)
 3 drugs 30 (24.4) 4 (6.7) 26 (41.3)
 4 drugs 1 (0.8) 0 (0) 1 (1.6)
Medication, n (%)
 SU 63 (51.2) 63 (100) 0 (0) -
 Glimepiride 25 (20.3) 25 (39.7) 0 (0) -
 Gliclazide 36 (29.3) 36 (57.1) 0 (0) -
 Glibenclamide 2 (1.6) 2 (3.2) 0 (0) -
 High-dose SU 10 (8.1) 10 (15.9) 0 (0) -
 TZD 21 (17.0) 11 (17.5) 10 (16.7) 0.907
 BG 49 (39.8) 26 (41.3) 23 (38.3) 0.739
 α-GI 13 (10.6) 7 (11.1) 6 (10.0) 0.841
 Glinide 2 (1.6) 0 (0) 2 (3.3) 0.144
 DPP4 inhibitor 75 (61.0) 32 (50.8) 43 (71.7) 0.018
 GLP1RA 4 (3.3) 3 (4.8) 1 (1.7) 0.333
 SGLT2 inhibitor 1 (0.8) 0 (0) 1 (1.7) 0.488
  1. Data are mean ± SD or n (%). P values are for differences between the SU and non-SU groups.
  2. *p < 0.05 by Mann–Whitney’s U test.
  3. p < 0.05 by χ2 test.